AstraZeneca signs $40 million AI drug discovery deal with insitro for cardiometabolic diseases
AstraZeneca has entered a strategic collaboration with insitro to develop therapies for hard-to-treat cardiometabolic diseases, reportedly valued at $40 million. It was announced on 15 October, and the Hungarian press (Portfolio) highlighted liver and heart diseases.
Who is affected and how
- pharmaceuticals
- Another large drugmaker is forming a development partnership with an external AI platform provider, a benchmark for collaboration models.
- health policy
- Development targeting liver and heart diseases could affect treatment options in the long term.
Sources
- AstraZeneca strikes $40 million AI drug discovery deal with insitroreuters · Oct 15, 2026
- AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitrowsj · Oct 15, 2026
- AstraZeneca inks $1.5B insitro deal for AI-enabled target discovery of liver, heart disease drugsfierce biotech · Oct 15, 2026
- insitro and AstraZeneca strike up to $1.5B AI drug-discovery partnership for liver and heart diseasedealroom · Oct 16, 2026
- AstraZeneca announces new strategic collaboration with insitro to use advanced AI systems to develop transformative therapeutics for difficult to treat cardiometabolic diseasesastrazeneca · Oct 15, 2026
- insitro Announces a Strategic Collaboration with AstraZeneca for AI-enabled Discovery of Novel Therapeutics for MASH and Cardiomyopathies - BioSpacebiospace.com · Oct 15, 2026
- A new era in medicine: artificial intelligence deployed against severe liver and heart diseases - Portfolio.huportfolio.hu · Oct 15, 2026 · magyar
Machine-generated summary based on the titles and excerpts of the source articles. The source article is the authority for the facts. News monitoring, not medical advice: consult a doctor for health decisions.